Acknowledgements
The authors thank the patients and their families for their permission
to include their information in DECIPHER. The authors would also like to
thank all registered DECIPHER users for depositing and seeking consent
to share patient data. The DECIPHER project was given a favourable NRES
REC opinion by Cambridge South (previously Cambridgeshire 4 REC), REC
reference 04/MRE05/50, in November 2004. DECIPHER submits annual
progress reports to ensure this favourable opinion applies for the
duration of the research. DECIPHER is supported by Wellcome funding,
grant WT206194. Helen Firth is supported by The Wellcome award
WT200990/Z/16/Z Designing, developing and delivering integrated
foundations for genomic medicine. Fiona Cunnigham and Sarah E. Hunt
receive funding from the Wellcome Trust (grant number WT108749/Z/15/Z)
and the European Molecular Biology Laboratory. This research was funded
in whole, or in part, by the Wellcome Trust [Grant numbers WT206194,
WT200990/Z/16/Z, WT108749/Z/15/Z]. For the purpose of open access, the
author has applied a CC BY public copyright licence to any Author
Accepted Manuscript version arising from this submission. Matthew Hurles
is a co-founder, shareholder and non-executive director of Congenica
Ltd., a diagnostic software company. Data sharing not applicable to this
article as no datasets were generated or analysed during the current
study.